AC Immune SA reports results for the quarter ended September 30 - Earnings Summary

AC Immune SA reported a quarterly adjusted loss of 16 rappen per share for the quarter ended September 30, an improvement from a loss of 5 rappen in the same quarter last year. Revenue fell 96.3% to CHF939,000, exceeding analyst expectations of CHF813,290. The company reported a total loss of CHF15.86 million. Despite the losses, AC Immune shares rose 10% this quarter, with a current average analyst rating of "strong buy" and a 12-month price target of $8.50, indicating a potential upside of 62.6% from the last closing price of $3.18.